Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules
Forte Biosciences, Inc. Announces First Quarter 2024 Results and Provides Business Update
Anova to Manage Study of DB107 Following Newly Awarded $11.8M CIRM Grant [Yahoo! Finance]
Forte Biosciences, Inc. (NASDAQ: FBRX) was upgraded by analysts at LADENBURG THALM/SH SH from a "neutral" rating to a "buy" rating. They now have a $2.75 price target on the stock.
Forte Biosciences, Inc. Announces 2023 Results and Provides Business Update